Preconception Cardiometabolic Screening for Future Pregnancy Health

Abstract

Cardiometabolic health exerts a profound influence on maternal and fetal outcomes, with preconception screening emerging as a pivotal strategy for risk stratification and intervention. This review synthesizes current scientific evidence and clinical guidelines on the importance of cardiometabolic screening before conception, elucidating its impact on pregnancy morbidity and long-term health trajectories for both mother and offspring. The article explores epidemiology, underlying mechanisms, risk factors, clinical assessment, management, and the evolving landscape of preventive strategies, providing actionable insights for healthcare professionals to optimize reproductive health through evidence-based, preconception-focused care.

Introduction

Cardiometabolic disorders including hypertension, dyslipidemia, obesity, and impaired glucose tolerance are increasingly recognized as determinants of adverse pregnancy outcomes. Emerging data underscore the importance of identifying and optimizing cardiometabolic health prior to conception, thereby reducing risks for gestational complications such as preeclampsia, gestational diabetes mellitus (GDM), preterm birth, and future cardiovascular disease (CVD) in both mothers and their children. This review aims to provide a comprehensive, evidence-based overview of preconception cardiometabolic screening, integrating recent research findings, clinical relevance, and guideline recommendations for reproductive-aged women.

Epidemiology / Disease Burden

The global prevalence of cardiometabolic risk factors among women of reproductive age is rising, mirroring broader trends in the general population. Obesity rates have more than doubled over the past three decades, with approximately 25–30% of women entering pregnancy overweight or obese. The incidence of pregestational diabetes and hypertension is also increasing, contributing to a growing burden of adverse pregnancy outcomes. Notably, women with pre-existing cardiometabolic conditions face a two- to fourfold increased risk of preeclampsia, GDM, fetal growth restriction, and stillbirth. Furthermore, the intergenerational transmission of metabolic risk underscores the public health imperative for early detection and intervention.

Pathophysiology

Cardiometabolic dysfunction prior to conception can disrupt the delicate physiological adaptations required for a healthy pregnancy. Obesity and insulin resistance impair endothelial function, promote systemic inflammation, and disturb placental development, increasing susceptibility to preeclampsia and GDM. Dyslipidemia and chronic hypertension further exacerbate vascular dysfunction, while subclinical atherosclerosis may limit uteroplacental perfusion. These pathophysiological changes not only compromise fetal growth and development but also establish a trajectory toward lifelong cardiometabolic disease for both mother and child.

Risk Factors

Major risk factors for adverse cardiometabolic profiles in women planning pregnancy include advanced maternal age, family history of diabetes or CVD, obesity (BMI ≥25 kg/m2), polycystic ovary syndrome (PCOS), sedentary lifestyle, unhealthy dietary patterns, and prior history of gestational complications. Additional contributors include smoking, chronic kidney disease, autoimmune disorders, and certain genetic predispositions. Identifying these risk factors during preconception consultations enables targeted screening and early intervention.

Clinical Features

Cardiometabolic risk factors may be clinically silent prior to pregnancy, necessitating systematic evaluation. Women may present with subtle indicators such as elevated BMI, mild hypertension, or biochemical abnormalities (e.g., fasting hyperglycemia, increased LDL cholesterol). In PCOS, hirsutism, menstrual irregularities, and acanthosis nigricans may signal underlying insulin resistance. Recognizing these clinical features is essential for comprehensive risk assessment and for guiding subsequent diagnostic workup.

Diagnosis

Preconception screening encompasses a combination of clinical assessment and laboratory investigations. Recommended evaluations include measurement of BMI, blood pressure, fasting plasma glucose or HbA1c, lipid profile, and assessment for metabolic syndrome components. In high-risk populations, additional tests such as oral glucose tolerance testing, renal function assessment, thyroid function tests, and inflammatory markers may be indicated. Structured risk calculators (e.g., Framingham or QRISK) can further refine cardiovascular risk stratification.

Treatment & Management

Early intervention is crucial for optimizing pregnancy outcomes in women with identified cardiometabolic risk. Lifestyle modification including tailored nutritional counseling, physical activity promotion, and weight management forms the cornerstone of preconception care. For women with established hypertension, diabetes, or dyslipidemia, pharmacologic optimization and transition to pregnancy-safe medications are recommended. Multidisciplinary management involving obstetricians, endocrinologists, dietitians, and primary care providers ensures comprehensive care and monitoring throughout the preconception and antenatal periods.

Recent Advances / Emerging Therapies

The landscape of preconception cardiometabolic care is rapidly evolving. Novel biomarkers (e.g., adipokines, placental growth factor) and advanced imaging modalities hold promise for earlier detection of subclinical disease. Digital health tools including mobile apps and remote monitoring platforms are enhancing patient engagement and facilitating longitudinal risk management. Pharmacologic advancements, such as the use of SGLT2 inhibitors and GLP-1 receptor agonists in preconception metabolic optimization, are under investigation, though safety data in pregnancy remain limited. Ongoing research into epigenetic modulation and microbiome-targeted interventions may further refine future preventive strategies.

Guideline Recommendations

Major professional organizations, including the American College of Obstetricians and Gynecologists (ACOG), Endocrine Society, and the World Health Organization (WHO), advocate for systematic preconception screening of cardiometabolic risk factors. Guidelines emphasize early identification and management of obesity, hypertension, dyslipidemia, and glucose intolerance. Preconception counseling should include individualized risk assessment, education on lifestyle modification, and medication review for teratogenicity. Women with significant risk should be referred for specialist input and multidisciplinary care planning.

Conclusion

Preconception cardiometabolic screening represents a critical opportunity to optimize maternal and fetal health, reduce pregnancy-related morbidity, and disrupt the cycle of intergenerational cardiometabolic disease. Clinicians should integrate evidence-based screening and intervention strategies into routine preconception care, guided by current research and clinical guidelines. Ongoing advances in risk assessment and personalized intervention offer promise for further improving reproductive and long-term outcomes. As the prevalence of cardiometabolic disorders continues to rise, proactive, guideline-driven preconception care must become an essential component of womens health services worldwide.